Global Cancer Profiling Market Expected to Deliver Dynamic Progression until 2026 | By Agendia, Genomic Health Inc., Oxford Gene Technology Ltd., NeoGenomics Laboratories, etc.

FactMR has published a new research report titled “Global Cancer Profiling Market Expected to Deliver Dynamic Progression until 2026” to its online database that tries to unveil the various scenarios prevailing in the cancer profiling market. This assessment delivers a smart compilation of primary and secondary data which provides a clear insight about the future plans expected to impact the Cancer Profiling Market. This study comprises of prominent data which makes it a beneficial source for investors, analysts and industry experts to acquire necessary knowledge associated to the fundamental market trends, opportunities and growth drivers during 2017-2026.

Request 100 Page Sample Report from Here - https://www.factmr.com/connectus/sample?flag=S&rep_id=358

Cancer profiling offers information on the gene causing cancer along with the key insights on the mechanism of cancer. The U.S. Food and Drug Administration (FDA) recently approved first-of-its-kind cancer gene profiling. The test looks for mutations in various cancer genes at once, offering a complete profile on driving forces of tumor in patients. The key companies in the cancer profiling are coming up with new products to meet the requirements of life science and molecular diagnostics companies. The market for cancer profiling is also seeing an increase in demand for Next-Generation Sequencing (NGS). Pharmaceutical companies are also using molecular profiling through NSG to produce therapeutic vaccines for cancer.

According to a study by FactMR, the global market for cancer profiling is likely to experience solid growth. The global market for cancer profiling is also projected to bring in US$ 122,129.6 million revenue by 2026 end. Technological advancements, increasing cancer incidences, tumor profiling using biomarkers, the rise in funds for cancer research, are some of the major factors resulting in the growth of cancer profiling market. However, lack of skilled professionals and infrastructure are hampering the growth of the global market for cancer profiling.

Next-generation sequencing technique is likely to be the most-preferred cancer profiling technique. Experiencing a solid growth, next-generation sequencing technique is projected to exceed US$ 61,900 million revenue by 2026 end. Owing to the reduced sequencing cost, technology advancements in platforms used for sequencing, and rising awareness on next-generation sequencing services and products, the next-generation sequencing technique will experience growth in the market.

Compared to the various end-users of cancer profiling, pharmaceutical and biotech companies are likely to emerge as the biggest users of cancer profiling. Pharmaceutical and biotech companies are projected to create an incremental opportunity surpassing US$ 40,600 million between 2017 and 2026. Factors such as offering better-targeted therapy and medicine for cancer treatment, correct prediction of various types of cancer, and reducing adverse drug reaction by offering correct dosage and formulation are driving the use of cancer profiling by pharmaceutical and biotech companies.

Browse Market Report with TOC Here - https://www.factmr.com/report/358/cancer-profiling-market

Cancer profiling is used for research, prognosis, personalized medicine, biomarker discovery. However, cancer profiling is likely to find the largest application in diagnosis. Gaining considerable growth, diagnosis is anticipated to create an absolute dollar opportunity of over US$ 32,200 million between 2017 and 2026. Cancer profiling plays an important role in diagnosis, as it helps physicians in understanding cancer tumor and identifying type of cancer. It also helps in taking appropriate decisions, avoiding ‘over-treatment’ of cancer patients.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of global cancer profiling market through 2026, which include Agendia, Genomic Health Inc., Oxford Gene Technology Ltd., NeoGenomics Laboratories, RiboMed Biotechnologies Inc., BioTheranostics, Proteome Sciences PLC, Illumina, Inc. (U.S.), GenScript, Caris Life Sciences, and Roche Holdings.

Table of Content:

Global Economic Outlook
Global Cancer Profiling Market - Executive Summary
Global Cancer Profiling Market Overview
3.1. Introduction

       3.1.1. Global Cancer Profiling Market Taxonomy

       3.1.2. Global Cancer Profiling Market Definition

Continued…………..

Grab Customized Market Report from Here - https://www.factmr.com/checkout/358/S

About FactMr

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

FactMR
11140 Rockville Pike
Suite 400, Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/

This release was published on openPR.